Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 34 | 2023 | 386 | 10.490 |
Why?
|
| Liver Neoplasms | 36 | 2023 | 738 | 9.640 |
Why?
|
| Liver Transplantation | 29 | 2023 | 1271 | 7.010 |
Why?
|
| Chemoembolization, Therapeutic | 7 | 2023 | 36 | 3.040 |
Why?
|
| Bile Duct Neoplasms | 7 | 2023 | 79 | 2.930 |
Why?
|
| Cholangiocarcinoma | 6 | 2023 | 66 | 2.770 |
Why?
|
| Hepatitis C, Chronic | 8 | 2022 | 126 | 2.260 |
Why?
|
| Antiviral Agents | 12 | 2022 | 512 | 2.160 |
Why?
|
| Transplants | 2 | 2023 | 40 | 1.740 |
Why?
|
| Gastroenterologists | 2 | 2023 | 31 | 1.660 |
Why?
|
| Sofosbuvir | 4 | 2017 | 18 | 1.430 |
Why?
|
| Hepatitis C | 4 | 2022 | 210 | 1.340 |
Why?
|
| Radiosurgery | 3 | 2020 | 272 | 1.330 |
Why?
|
| Liver Cirrhosis | 11 | 2023 | 300 | 1.310 |
Why?
|
| Fatty Liver | 3 | 2023 | 125 | 1.290 |
Why?
|
| Gastroenterology | 4 | 2023 | 140 | 1.240 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2022 | 24 | 1.230 |
Why?
|
| Liver | 3 | 2023 | 1230 | 1.100 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2023 | 70 | 1.080 |
Why?
|
| Tissue and Organ Procurement | 5 | 2023 | 311 | 1.020 |
Why?
|
| Humans | 70 | 2023 | 86678 | 1.000 |
Why?
|
| Liver Diseases | 3 | 2023 | 241 | 0.980 |
Why?
|
| Viral Load | 4 | 2017 | 150 | 0.920 |
Why?
|
| Ribavirin | 2 | 2016 | 58 | 0.920 |
Why?
|
| Brachytherapy | 2 | 2021 | 119 | 0.890 |
Why?
|
| End Stage Liver Disease | 3 | 2023 | 62 | 0.860 |
Why?
|
| Simeprevir | 3 | 2016 | 4 | 0.840 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2022 | 25 | 0.840 |
Why?
|
| Committee Membership | 1 | 2021 | 4 | 0.820 |
Why?
|
| Hemostatics | 1 | 2022 | 56 | 0.820 |
Why?
|
| alpha-Fetoproteins | 4 | 2023 | 45 | 0.820 |
Why?
|
| Career Mobility | 1 | 2021 | 31 | 0.800 |
Why?
|
| Blood Coagulation Disorders | 1 | 2022 | 63 | 0.790 |
Why?
|
| Societies, Scientific | 1 | 2021 | 44 | 0.790 |
Why?
|
| Yttrium Radioisotopes | 6 | 2023 | 46 | 0.780 |
Why?
|
| Ablation Techniques | 1 | 2020 | 34 | 0.750 |
Why?
|
| Leadership | 1 | 2021 | 134 | 0.720 |
Why?
|
| Hepatitis B, Chronic | 2 | 2016 | 32 | 0.710 |
Why?
|
| Organ Transplantation | 1 | 2023 | 265 | 0.710 |
Why?
|
| Faculty, Medical | 1 | 2021 | 179 | 0.690 |
Why?
|
| Transplant Recipients | 2 | 2023 | 122 | 0.670 |
Why?
|
| Hepacivirus | 4 | 2022 | 160 | 0.660 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 212 | 0.650 |
Why?
|
| Catheter Ablation | 1 | 2020 | 233 | 0.640 |
Why?
|
| Societies, Medical | 2 | 2021 | 573 | 0.640 |
Why?
|
| Endosonography | 1 | 2019 | 96 | 0.640 |
Why?
|
| Living Donors | 8 | 2023 | 339 | 0.620 |
Why?
|
| Fluorenes | 1 | 2017 | 8 | 0.610 |
Why?
|
| Pancreas | 1 | 2019 | 239 | 0.600 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 105 | 0.590 |
Why?
|
| Virus Activation | 1 | 2016 | 41 | 0.570 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 266 | 0.570 |
Why?
|
| Benzimidazoles | 1 | 2017 | 140 | 0.550 |
Why?
|
| Peritonitis | 1 | 2015 | 29 | 0.540 |
Why?
|
| Ascites | 1 | 2015 | 56 | 0.530 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 110 | 0.510 |
Why?
|
| Drainage | 1 | 2015 | 157 | 0.500 |
Why?
|
| Neoplasms | 2 | 2023 | 2898 | 0.500 |
Why?
|
| Liver Failure | 1 | 2014 | 79 | 0.490 |
Why?
|
| Bacterial Infections | 1 | 2015 | 182 | 0.470 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 895 | 0.470 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 645 | 0.450 |
Why?
|
| Retrospective Studies | 16 | 2023 | 8496 | 0.440 |
Why?
|
| Treatment Outcome | 15 | 2023 | 7998 | 0.430 |
Why?
|
| Logistic Models | 5 | 2017 | 1188 | 0.410 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2022 | 19 | 0.410 |
Why?
|
| Interferon-alpha | 1 | 2010 | 234 | 0.360 |
Why?
|
| Middle Aged | 15 | 2021 | 25040 | 0.350 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 977 | 0.340 |
Why?
|
| Hepatectomy | 2 | 2020 | 166 | 0.330 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 194 | 0.330 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 364 | 0.320 |
Why?
|
| United States | 13 | 2023 | 6681 | 0.320 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2008 | 52 | 0.310 |
Why?
|
| Microspheres | 3 | 2023 | 101 | 0.300 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2504 | 0.290 |
Why?
|
| Probiotics | 1 | 2008 | 81 | 0.290 |
Why?
|
| Male | 16 | 2021 | 40988 | 0.290 |
Why?
|
| Guanine | 2 | 2016 | 208 | 0.270 |
Why?
|
| Hepatitis B virus | 2 | 2015 | 43 | 0.260 |
Why?
|
| Hepatitis B | 2 | 2015 | 74 | 0.250 |
Why?
|
| Female | 15 | 2021 | 44550 | 0.250 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 1939 | 0.250 |
Why?
|
| Lactulose | 1 | 2023 | 20 | 0.230 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 395 | 0.230 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 42 | 0.230 |
Why?
|
| Employment | 1 | 2023 | 52 | 0.230 |
Why?
|
| Long-Term Care | 1 | 2023 | 61 | 0.220 |
Why?
|
| Hemostasis | 1 | 2022 | 21 | 0.220 |
Why?
|
| RNA, Viral | 2 | 2016 | 329 | 0.210 |
Why?
|
| Hepatitis, Chronic | 1 | 2022 | 5 | 0.210 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2022 | 23 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2023 | 4214 | 0.210 |
Why?
|
| Women, Working | 1 | 2021 | 7 | 0.210 |
Why?
|
| Aged | 10 | 2021 | 18423 | 0.200 |
Why?
|
| Genotype | 2 | 2017 | 1852 | 0.200 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 8 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 861 | 0.190 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2020 | 34 | 0.190 |
Why?
|
| Physicians, Women | 1 | 2021 | 53 | 0.190 |
Why?
|
| Liver Function Tests | 1 | 2020 | 93 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 238 | 0.190 |
Why?
|
| Hepatic Artery | 1 | 2021 | 83 | 0.190 |
Why?
|
| Graft Survival | 4 | 2021 | 885 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1204 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2020 | 289 | 0.170 |
Why?
|
| Heart Transplantation | 2 | 2023 | 705 | 0.170 |
Why?
|
| Transaminases | 1 | 2019 | 34 | 0.170 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 25 | 0.170 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 132 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2020 | 328 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 221 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2019 | 81 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 1313 | 0.160 |
Why?
|
| Education, Medical | 1 | 2021 | 234 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.160 |
Why?
|
| Risk Factors | 5 | 2019 | 5420 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 849 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.160 |
Why?
|
| Internal Medicine | 1 | 2021 | 349 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2023 | 1065 | 0.150 |
Why?
|
| Obesity | 2 | 2017 | 964 | 0.150 |
Why?
|
| Tenofovir | 1 | 2016 | 7 | 0.150 |
Why?
|
| Curriculum | 1 | 2021 | 543 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2021 | 2264 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2019 | 303 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 385 | 0.140 |
Why?
|
| Hypertension, Portal | 1 | 2016 | 47 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 263 | 0.130 |
Why?
|
| Genomics | 1 | 2020 | 720 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Coinfection | 1 | 2015 | 58 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 114 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1001 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2015 | 295 | 0.120 |
Why?
|
| Recurrence | 2 | 2022 | 1139 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2016 | 2768 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 3680 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 5214 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1718 | 0.120 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 365 | 0.120 |
Why?
|
| Adult | 10 | 2022 | 25659 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 230 | 0.110 |
Why?
|
| Donor Selection | 2 | 2023 | 68 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2021 | 1010 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2015 | 464 | 0.100 |
Why?
|
| North America | 2 | 2023 | 180 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 747 | 0.090 |
Why?
|
| Attitude | 2 | 2023 | 127 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 1 | 2009 | 54 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1015 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2601 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2009 | 209 | 0.080 |
Why?
|
| Lactobacillus plantarum | 1 | 2008 | 4 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 182 | 0.080 |
Why?
|
| Saccharomyces | 1 | 2008 | 21 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6513 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2023 | 629 | 0.080 |
Why?
|
| Antibodies | 1 | 2009 | 350 | 0.080 |
Why?
|
| Quality of Life | 1 | 2015 | 1585 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 142 | 0.070 |
Why?
|
| Chicago | 1 | 2010 | 1380 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 865 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 5980 | 0.060 |
Why?
|
| Blood Group Incompatibility | 1 | 2023 | 18 | 0.060 |
Why?
|
| Necrosis | 1 | 2023 | 204 | 0.060 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 8984 | 0.060 |
Why?
|
| Bilirubin | 1 | 2023 | 125 | 0.060 |
Why?
|
| Capecitabine | 1 | 2022 | 96 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 133 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 136 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 336 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 159 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 107 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1864 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 612 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 266 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 105 | 0.050 |
Why?
|
| Career Choice | 1 | 2021 | 142 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 944 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 22 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 267 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 226 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 361 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 860 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 1686 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 204 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3642 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1578 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2020 | 695 | 0.040 |
Why?
|
| Adiposity | 1 | 2017 | 70 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 98 | 0.040 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 8 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 686 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 175 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1169 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 229 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 756 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2015 | 9 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 636 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 360 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 770 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 684 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 455 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1019 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 11356 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 173 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 204 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 235 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2207 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 26590 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1753 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1532 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1802 | 0.010 |
Why?
|